Humulin M3 Kwikpen (Mixture 3) (Insulin Human)

Humulin M3 Kwikpen (Mixture 3) is used as an insulin replacement therapy in patients whose bodies do not produce sufficient insulin or who have impaired insulin utilization.

• Treatment of Type 1 diabetes mellitus
• Treatment of Type 2 diabetes mellitus when oral agents are insufficient
• Adjunct to diet and exercise for glycemic control
• Preferred option when a mixed‑insulin regimen is desired
• Provides both basal (intermediate) and prandial (rapid) insulin coverage in a single injection

• Humulin M3 Kwikpen contains human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers intracellular signaling cascades that increase glucose transporter translocation, enhance glucose uptake, and promote glycogen synthesis while suppressing hepatic gluconeogenesis, thereby lowering blood glucose concentrations.

Adverse reactions to Humulin M3 Kwikpen may vary in frequency and severity.

Common

• Mild hypoglycemia (low blood sugar)
• Injection site redness, swelling or itching
• Lipodystrophy (localized fat loss or accumulation)
• Weight gain
• Transient headache

Serious

• Severe hypoglycemia with neuroglycopenic symptoms
• Allergic reactions such as urticaria, angioedema or anaphylaxis
• Persistent hyperglycemia indicating possible insulin resistance
• Edema or heart failure exacerbation in susceptible individuals

When using Humulin M3 Kwikpen, certain precautions help minimize risks.

• Verify the correct pen and dose before each injection.
• Rotate injection sites to reduce lipodystrophy.
• Monitor blood glucose regularly, especially during dose changes.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Pregnant or breastfeeding individuals should consult a healthcare professional before use.
• Store the pen according to the manufacturer’s instructions and discard after the indicated period once opened.

Humulin M3 Kwikpen can interact with several medications and substances.

Avoid

• Other insulin products or concentrated insulin formulations that may cause stacking.
• Beta‑blockers that can mask hypoglycemia symptoms.
• MAO inhibitors that may potentiate insulin’s glucose‑lowering effect.

Use with caution

• Oral hypoglycemic agents (e.g., sulfonylureas, meglitinides) as they increase hypoglycemia risk.
• Corticosteroids, thiazide diuretics, and growth hormone, which may raise blood glucose.
• Alcohol, especially in excess, because it can cause unpredictable glucose fluctuations.